促胃肠动力药的研究进展及临床应用评价  

Progress in the Study of Prokinetic Agents and Evaluation on Their Clinical Application

作　　者：张玉蓓[1] 

机构地区：[1]广西壮族自治区南溪山医院药剂科,桂林市541002

出　　处：《中国医院用药评价与分析》2006年第6期336-339,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:对促胃肠动力药的研究进展及临床应用现状进行分析评价,为其临床应用提供参考。方法:查阅国内外近期相关文献,进行综合归纳分析。结果及结论:胃肠动力药在治疗反流性食管炎、功能性消化不良、胃轻瘫、慢性胃炎、功能性便秘、慢性特发性假性肠梗阻、肠应激综合征、糖尿病神经原性膀胱等方面都显示出了很好的疗效,高选择性5-HT4受体激动剂莫沙必利和胃肠双动力药伊托必利,疗效更加确切,不良反应更少,为胃肠动力障碍性疾病的治疗提供了更有价值的研究空间。OBJECTIVE ： To analyze and evaluate the progress in the study of prokinetic agents and the application status quo of this preparation for the reference of their rational use in the clinic. METHODS： The related literatures both home and abroad were reviewed and analyzed inductively. RESULTS ＆ CONCLUSION： Prokinetic agents showed satisfactory outcome in the treatment of reflux esophagitis, functional dyspepsia, gastroparesis, chronic gastritis, functional constipation, chronic idiopathic intestinal pseudo - obstruction, irritable bowel syndrome, diabetic neurogenic bladder, etc. in particular the mosapride, a 5 - HT4 receptor agonist that with high selectivity and itopride, which showed a more exact clinical effect yet of less ADRs, this provides a more valuable space for the study of therapy for gastrointestinal motility disorders.

关 键 词：胃肠动力障碍性疾病 促胃肠动力药 临床应用进展 

分 类 号：R975[医药卫生—药品]